Literature DB >> 3871615

Juvenile primary fibromyalgia syndrome. A clinical study of thirty-three patients and matched normal controls.

M B Yunus, A T Masi.   

Abstract

Primary fibromyalgia syndrome (PFS) is a common and characteristic rheumatologic condition manifested by diffuse musculoskeletal aches, pains, and stiffness frequently modulated by various factors, e.g., weather, physical activity, sleep quality, and anxiety/stress, and accompanied by discrete tender points at typical soft tissue sites. Although well-recognized in adults, this entity has not been reported separately in juveniles. This study documents PFS in 33 juveniles who presented at age 17 or younger and compares their findings with those in age- and sex-matched normal control subjects. As in adult PFS patients, associated non-musculoskeletal symptoms were common, including fatigue, poor sleep, anxiety/stress, headaches, and paresthesias. Physical examination revealed multiple tender points at characteristic soft tissue sites and no objective evidence of arthritis. Routine laboratory test results were normal or negative. Juvenile PFS is often misdiagnosed. Recognition of this common rheumatologic condition in juveniles is important in order to avoid unwarranted investigations and improper management.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871615     DOI: 10.1002/art.1780280205

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  69 in total

1.  Chronic musculoskeletal and other idiopathic pain syndromes.

Authors:  P N Malleson; H Connell; S M Bennett; C Eccleston
Journal:  Arch Dis Child       Date:  2001-03       Impact factor: 3.791

Review 2.  Efficacy and safety of meditative movement therapies in fibromyalgia syndrome: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Jost Langhorst; Petra Klose; Gustav J Dobos; Kathrin Bernardy; Winfried Häuser
Journal:  Rheumatol Int       Date:  2012-02-15       Impact factor: 2.631

3.  Preliminary evidence of altered biomechanics in adolescents with juvenile fibromyalgia.

Authors:  Soumitri Sil; Staci Thomas; Christopher DiCesare; Daniel Strotman; Tracy V Ting; Gregory Myer; Susmita Kashikar-Zuck
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-01       Impact factor: 4.794

4.  A Qualitative Examination of a New Combined Cognitive-Behavioral and Neuromuscular Training Intervention for Juvenile Fibromyalgia.

Authors:  Susmita Kashikar-Zuck; Susan T Tran; Kimberly Barnett; Maggie H Bromberg; Daniel Strotman; Soumitri Sil; Staci M Thomas; Naomi Joffe; Tracy V Ting; Sara E Williams; Gregory D Myer
Journal:  Clin J Pain       Date:  2016-01       Impact factor: 3.442

5.  Fibromyalgia: Does it Exist?

Authors:  O G Zadorozny
Journal:  Can Fam Physician       Date:  1990-09       Impact factor: 3.275

Review 6.  The adolescent with rheumatic disease.

Authors:  R Sathananthan; J David
Journal:  Arch Dis Child       Date:  1997-10       Impact factor: 3.791

7.  Long-term outcomes of adolescents with juvenile-onset fibromyalgia in early adulthood.

Authors:  Susmita Kashikar-Zuck; Natoshia Cunningham; Soumitri Sil; Maggie H Bromberg; Anne M Lynch-Jordan; Daniel Strotman; James Peugh; Jennie Noll; Tracy V Ting; Scott W Powers; Daniel J Lovell; Lesley M Arnold
Journal:  Pediatrics       Date:  2014-02-24       Impact factor: 7.124

Review 8.  Complementary and integrative methods in fibromyalgia.

Authors:  Ather Ali; Paul L McCarthy
Journal:  Pediatr Rev       Date:  2014-12

Review 9.  Adult growth hormone deficiency in patients with fibromyalgia.

Authors:  Robert M Bennett
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

10.  Quality of life and emotional functioning in youth with chronic migraine and juvenile fibromyalgia.

Authors:  Susmita Kashikar-Zuck; Marium Zafar; Kimberly A Barnett; Brandon S Aylward; Daniel Strotman; Shalonda K Slater; Janelle R Allen; Susan L Lecates; Marielle A Kabbouche; Tracy V Ting; Andrew D Hershey; Scott W Powers
Journal:  Clin J Pain       Date:  2013-12       Impact factor: 3.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.